Loading clinical trials...
Loading clinical trials...
Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer (PRIORITY): a Prospective Single Center, Open Label, Phase II Study
Conditions
Interventions
Sintilimab
Anlotinib
Start Date
February 1, 2024
Primary Completion Date
February 28, 2025
Completion Date
February 1, 2030
Last Updated
January 25, 2024
NCT04165798
NCT06667908
NCT06875310
NCT07046923
NCT07222566
NCT06667076
Lead Sponsor
Ningbo No.2 Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions